請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61363
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 曾宇鳳,孔繁璐 | |
dc.contributor.author | Chia-Yun Chang | en |
dc.contributor.author | 張嘉芸 | zh_TW |
dc.date.accessioned | 2021-06-16T13:01:39Z | - |
dc.date.available | 2018-08-01 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-07 | |
dc.identifier.citation | 1. Field, J. R.; Walker, A. G.; Conn, P. J., Targeting glutamate synapses in schizophrenia. Trends in molecular medicine 2011, 17 (12), 689-98.
2. Paoletti, P.; Neyton, J., NMDA receptor subunits: function and pharmacology. Current opinion in pharmacology 2007, 7 (1), 39-47. 3. Kleckner, N. W.; Dingledine, R., Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988, 241 (4867), 835-7. 4. Coyle, J. T.; Tsai, G., The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 2004, 174 (1), 32-8. 5. Schell, M. J., The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 2004, 359 (1446), 943-64. 6. Shleper, M.; Kartvelishvily, E.; Wolosker, H., D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. The Journal of Neuroscience 2005, 25 (41), 9413-7. 7. Mothet, J. P.; Parent, A. T.; Wolosker, H.; Brady, R. O., Jr.; Linden, D. J.; Ferris, C. D.; Rogawski, M. A.; Snyder, S. H., D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proceedings of the National Academy of Sciences of the United States of America 2000, 97 (9), 4926-31. 8. Gong, X. Q.; Zabek, R. L.; Bai, D., D-Serine inhibits AMPA receptor-mediated current in rat hippocampal neurons. Canadian Journal of Physiology and Pharmacology 2007, 85 (5), 546-55. 9. Kaster, M. P.; Machado, D. G.; Santos, A. R.; Rodrigues, A. L., Involvement of NMDA receptors in the antidepressant-like action of adenosine. Pharmacological reports : PR 2012, 64 (3), 706-13. 10. Hashimoto, K.; Malchow, B.; Falkai, P.; Schmitt, A., Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience 2013. 11. Ferraris, D. V.; Tsukamoto, T., Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Current pharmaceutical design 2011, 17 (2), 103-11. 12. Miyamoto, S.; Miyake, N.; Jarskog, L. F.; Fleischhacker, W. W.; Lieberman, J. A., Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular psychiatry 2012, 17 (12), 1206-27. 13. Sacchi, S.; Rosini, E.; Pollegioni, L.; Molla, G., D-Amino Acid Oxidase Inhibitors as a Novel Class of Drugs for Schizophrenia Therapy. Current pharmaceutical design 2012. 14. Ono, K.; Shishido, Y.; Park, H. K.; Kawazoe, T.; Iwana, S.; Chung, S. P.; Abou El-Magd, R. M.; Yorita, K.; Okano, M.; Watanabe, T.; Sano, N.; Bando, Y.; Arima, K.; Sakai, T.; Fukui, K., Potential pathophysiological role of D-amino acid oxidase in schizophrenia: immunohistochemical and in situ hybridization study of the expression in human and rat brain. Journal of neural transmission (Vienna, Austria : 1996) 2009, 116 (10), 1335-47. 15. Adage, T.; Trillat, A. C.; Quattropani, A.; Perrin, D.; Cavarec, L.; Shaw, J.; Guerassimenko, O.; Giachetti, C.; Greco, B.; Chumakov, I.; Halazy, S.; Roach, A.; Zaratin, P., In vitro and in vivo pharmacological profile of AS057278, a selective D-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 2008, 18 (3), 200-14. 16. Ferraris, D.; Duvall, B.; Ko, Y. S.; Thomas, A. G.; Rojas, C.; Majer, P.; Hashimoto, K.; Tsukamoto, T., Synthesis and biological evaluation of D-amino acid oxidase inhibitors. J Med Chem 2008, 51 (12), 3357-9. 17. Smith, S. M.; Uslaner, J. M.; Yao, L.; Mullins, C. M.; Surles, N. O.; Huszar, S. L.; McNaughton, C. H.; Pascarella, D. M.; Kandebo, M.; Hinchliffe, R. M.; Sparey, T.; Brandon, N. J.; Jones, B.; Venkatraman, S.; Young, M. B.; Sachs, N.; Jacobson, M. A.; Hutson, P. H., The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine. J Pharmacol Exp Ther 2009, 328 (3), 921-30. 18. Duplantier, A. J.; Becker, S. L.; Bohanon, M. J.; Borzilleri, K. A.; Chrunyk, B. A.; Downs, J. T.; Hu, L. Y.; El-Kattan, A.; James, L. C.; Liu, S.; Lu, J.; Maklad, N.; Mansour, M. N.; Mente, S.; Piotrowski, M. A.; Sakya, S. M.; Sheehan, S.; Steyn, S. J.; Strick, C. A.; Williams, V. A.; Zhang, L., Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors. J Med Chem 2009, 52 (11), 3576-85. 19. Hondo, T.; Warizaya, M.; Niimi, T.; Namatame, I.; Yamaguchi, T.; Nakanishi, K.; Hamajima, T.; Harada, K.; Sakashita, H.; Matsumoto, Y.; Orita, M.; Takeuchi, M., 4-Hydroxypyridazin-3(2H)-one Derivatives as Novel D-Amino Acid Oxidase Inhibitors. Journal of Medicinal Chemistry 2013, 56 (9), 3582-3592. 20. Lai, C. H.; Lane, H. Y.; Tsai, G. E., Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naive patient with major depression. Biological psychiatry 2012, 71 (4), e9-e10. 21. Ashburn, T. T.; Thor, K. B., Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery 2004, 3 (8), 673-683. 22. Schnell, E.; Sizemore, M.; Karimzadegan, S.; Chen, L.; Bredt, D. S.; Nicoll, R. A., Direct interactions between PSD-95 and stargazin control synaptic AMPA receptor number. Proc Natl Acad Sci U S A 2002, 99 (21), 13902-7. 23. Halgren, T. A., Merck molecular force field .1. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996, 17 (5-6), 490-519. 24. Weber, L., JChem Base - ChemAxon. Chem World-Uk 2008, 5 (10), 65-66. 25. Hsu, K. C.; Chen, Y. F.; Lin, S. R.; Yang, J. M., iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. Bmc Bioinformatics 2011, 12. 26. Oostenbrink, C.; Soares, T. A.; van der Vegt, N. F. A.; van Gunsteren, W. F., Validation of the 53A6 GROMOS force field. Eur Biophys J Biophy 2005, 34 (4), 273-284. 27. Oguri, S., Screening of D-amino acid oxidase inhibitor by a new multi-assay method. Food chemistry 2007, 100 (2), 616. 28. Halgren, T. A., Merck molecular force field .5. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J Comput Chem 1996, 17 (5-6), 616-641. 29. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M., DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic acids research 2008, 36 (Database issue), D901-6. 30. Sparey, T.; Abeywickrema, P.; Almond, S.; Brandon, N.; Byrne, N.; Campbell, A.; Hutson, P. H.; Jacobson, M.; Jones, B.; Munshi, S.; Pascarella, D.; Pike, A.; Prasad, G. S.; Sachs, N.; Sakatis, M.; Sardana, V.; Venkatraman, S.; Young, M. B., The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors. Bioorg Med Chem Lett 2008, 18 (11), 3386-91. 31. Kawazoe, T.; Tsuge, H.; Imagawa, T.; Aki, K.; Kuramitsu, S.; Fukui, K., Structural basis of D-DOPA oxidation by D-amino acid oxidase: Alternative pathway for dopamine biosynthesis. Biochem Bioph Res Co 2007, 355 (2), 385-391. 32. Duplantier, A. J.; Becker, S. L.; Bohanon, M. J.; Borzilleri, K. A.; Chrunyk, B. A.; Downs, J. T.; Hu, L. Y.; El-Kattan, A.; James, L. C.; Liu, S. P.; Lu, J. M.; Maklad, N.; Mansour, M. N.; Mente, S.; Piotrowski, M. A.; Sakya, S. M.; Sheehan, S.; Steyn, S. J.; Strick, C. A.; Williams, V. A.; Zhang, L., Discovery, SAR, and Pharmacokinetics of a Novel 3-Hydroxyquinolin-2(1H)-one Series of Potent D-Amino Acid Oxidase (DAAO) Inhibitors. Journal of Medicinal Chemistry 2009, 52 (11), 3576-3585. 33. Abelo, A.; Andersson, T. B.; Antonsson, M.; Naudot, A. K.; Skanberg, I.; Weidolf, L., Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000, 28 (8), 966-972. 34. Lynch, T.; Price, A., The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007, 76 (3), 391-396. 35. Bymaster, F. P.; Hemrick-Luecke, S. K.; Perry, K. W.; Fuller, R. W., Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 1996, 124 (1-2), 87-94. 36. Borup, C.; Meidahl, B.; Petersen, I. M.; Vangtorp, A.; le Fevre Honore, P., An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness. Pharmacopsychiatria 1982, 15 (6), 183-6. 37. Miyashita, Y.; Li, Z. L.; Sasaki, S., Chemical-Pattern Recognition and Multivariate-Analysis for Qsar Studies. Trac-Trend Anal Chem 1993, 12 (2), 50-60. 38. Hoffman, B.; Cho, S. J.; Zheng, W. F.; Wyrick, S.; Nichols, D. E.; Mailman, R. B.; Tropsha, A., Quantitative structure-activity relationship modeling of dopamine D-1 antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. Journal of Medicinal Chemistry 1999, 42 (17), 3217-3226. 39. Zheng, W. F.; Tropsha, A., Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbor principle. J Chem Inf Comp Sci 2000, 40 (1), 185-194. 40. Ajay, A Unified Framework for Using Neural Networks to Build Qsars. Journal of Medicinal Chemistry 1993, 36 (23), 3565-3571. 41. Cramer, R. D.; Patterson, D. E.; Bunce, J. D., Comparative Molecular-Field Analysis (Comfa) .1. Effect of Shape on Binding of Steroids to Carrier Proteins. J Am Chem Soc 1988, 110 (18), 5959-5967. 42. Kubinyi, H.; Hamprecht, F. A.; Mietzner, T., Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. Journal of Medicinal Chemistry 1998, 41 (14), 2553-2564. 43. Perez, C.; Pastor, M.; Ortiz, A. R.; Gago, F., Comparative binding energy analysis of HIV-1 protease inhibitors: Incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. Journal of Medicinal Chemistry 1998, 41 (6), 836-852. 44. Hopfinger, A. J.; Wang, S.; Tokarski, J. S.; Jin, B. Q.; Albuquerque, M.; Madhav, P. J.; Duraiswami, C., Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J Am Chem Soc 1997, 119 (43), 10509-10524. 45. Hopfinger, A. J.; Reaka, A.; Venkatarangan, P.; Duca, J. S.; Wang, S., Construction of a virtual nigh throughput screen by 4D-QSAR analysis: Application to a combinatorial library of glucose inhibitors of glycogen phosphorylase b. J Chem Inf Comp Sci 1999, 39 (6), 1151-1160. 46. Iyer, M.; Hopfinger, A. J., Treating chemical diversity in QSAR analysis: Modeling diverse HIV-1 integrase inhibitors using 4D fingerprints. J Chem Inf Model 2007, 47 (5), 1945-1960. 47. Krasowski, M. D.; Hong, X. A.; Hopfinger, A. J.; Harrison, N. L., 4D-QSAR analysis of a set of propofol analogues: Mapping binding sites for an anesthetic phenol on the GABA(A) receptor. Journal of Medicinal Chemistry 2002, 45 (15), 3210-3221. 48. Yang, K.; Bai, H. J.; Qi, O. Y.; Lai, L. H.; Tang, C., Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol 2008, 4. 49. Xie, L.; Evangelidis, T.; Xie, L.; Bourne, P. E., Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir. Plos Comput Biol 2011, 7 (4). 50. Wei, Y. Y.; Fox, T.; Chambers, S. P.; Sintchak, J.; Coll, J. T.; Golec, J. M. C.; Swenson, L.; Wilson, K. P.; Charifson, P. S., The structures of caspases-1,-3,-7 and-8 reveal the basis for substrate and inhibitor selectivity. Chem Biol 2000, 7 (6), 423-432. 51. Turk, B. E.; Wong, T. Y.; Schwarzenbacher, R.; Jarrell, E. T.; Leppla, S. H.; Collier, R. J.; Liddington, R. C.; Cantley, L. C., The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat Struct Mol Biol 2004, 11 (1), 60-66. 52. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P., A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26 (1), 127-132. 53. Bitto, A.; Minutoli, L.; David, A.; Irrera, N.; Rinaldi, M.; Venuti, F. S.; Squadrito, F.; Altavilla, D., Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis. Crit Care 2012, 16 (1), R32. 54. Morabito, A.; Piccirillo, M. C.; Falasconi, F.; De Feo, G.; Del Giudice, A.; Bryce, J.; Di Maio, M.; De Maio, E.; Normanno, N.; Perrone, F., Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions. Oncologist 2009, 14 (4), 378-390. 55. Ishikawa, T.; Seto, M.; Banno, H.; Kawakita, Y.; Oorui, M.; Taniguchi, T.; Ohta, Y.; Tamura, T.; Nakayama, A.; Miki, H.; Kamiguchi, H.; Tanaka, T.; Habuka, N.; Sogabe, S.; Yano, J.; Aertgeerts, K.; Kamiyama, K., Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold. Journal of Medicinal Chemistry 2011, 54 (23), 8030-8050. 56. Oumata, N.; Bettayeb, K.; Ferandin, Y.; Demange, L.; Lopez-Giral, A.; Goddard, M. L.; Myrianthopoulos, V.; Mikros, E.; Flajolet, M.; Greengard, P.; Meijer, L.; Galons, H., Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J Med Chem 2008, 51 (17), 5229-42. 57. Yarden, Y.; Sliwkowski, M. X., Untangling the ErbB signalling network. Nat Rev Mol Cell Bio 2001, 2 (2), 127-137. 58. Gschwind, A.; Fischer, O. M.; Ullrich, A., Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4 (5), 361-370. 59. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; Mcguire, W. L., Human-Breast Cancer - Correlation of Relapse and Survival with Amplification of the Her-2 Neu Oncogene. Science 1987, 235 (4785), 177-182. 60. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A.; Press, M. F., Studies of the Her-2/Neu Proto-Oncogene in Human-Breast and Ovarian-Cancer. Science 1989, 244 (4905), 707-712. 61. Huang, S. M.; Harari, P. M., Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results. Invest New Drug 1999, 17 (3), 259-269. 62. Ronson, M.; Hammond, L. A.; Ferry, D.; Kris, M.; Tullo, A.; Murray, P. I.; Miller, V.; Averbuch, S.; Ochs, J.; Morris, C.; Feyereislova, A.; Swaisland, H.; Rowinsky, E. K., ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 2002, 20 (9), 2240-2250. 63. Hidalgo, M.; Siu, L. L.; Nemunaitis, J.; Rizzo, J.; Hammond, L. A.; Takimoto, C.; Eckhardt, S. G.; Tolcher, A.; Britten, C. D.; Denis, L.; Ferrante, K.; Von Hoff, D. D.; Silberman, S.; Rowinsky, E. K., Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19 (13), 3267-79. 64. Sipples, R., Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs 2006, 22 (1 Suppl 1), 28-34. 65. Ubersax, J. A.; Woodbury, E. L.; Quang, P. N.; Paraz, M.; Blethrow, J. D.; Shah, K.; Shokat, K. M.; Morgan, D. O., Targets of the cyclin-dependent kinase Cdk1. Nature 2003, 425 (6960), 859-864. 66. Lew, J.; Huang, Q. Q.; Qi, Z.; Winkfein, R. J.; Aebersold, R.; Hunt, T.; Wang, J. H., A Brain-Specific Activator of Cyclin-Dependent Kinase-5. Nature 1994, 371 (6496), 423-426. 67. Morgan, D. O., Principles of Cdk Regulation. Nature 1995, 374 (6518), 131-134. 68. Nurse, P., Universal control mechanism regulating onset of M-phase. Nature 1990, 344 (6266), 503-8. 69. Knippschild, U.; Gocht, A.; Wolff, S.; Huber, N.; Lohler, J.; Stoter, M., The casein kinase I family: participation in multiple cellular processes in eukaryotes. Cell Signal 2005, 17 (6), 675-689. 70. Gokhale, A.; Wirschell, M.; Sale, W. S., Regulation of dynein-driven microtubule sliding by the axonemal protein kinase CK1 in Chlamydomonas flagella. J Cell Biol 2009, 186 (6), 817-24. 71. Kloss, B.; Price, J. L.; Saez, L.; Blau, J.; Rothenfluh, A.; Wesley, C. S.; Young, M. W., The Drosophila clock gene double-time encodes a protein closely related to human casein kinase I epsilon. Cell 1998, 94 (1), 97-107. 72. Schwab, C.; DeMaggio, A. J.; Ghoshal, N.; Binder, L. I.; Kuret, J.; McGeer, P. L., Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative disease. Neurobiol Aging 2000, 21 (4), 503-510. 73. Elias, L.; Li, A. P.; Longmire, J., Cyclic Adenosine 3'-5'-Monophosphate-Dependent and 3'-5'-Independent Protein-Kinase in Acute Myeloblastic-Leukemia. Cancer Res 1981, 41 (6), 2182-2188. 74. Bustos, V. H.; Ferrarese, A.; Venerando, A.; Marin, O.; Allende, J. E.; Pinna, L. A., The first armadillo repeat is involved in the recognition and regulation of beta-catenin phosphorylation by protein kinase CK1. P Natl Acad Sci USA 2006, 103 (52), 19725-19730. 75. Protein Data Bank. http://www.pdb.org/pdb/home/home.do. 76. SWISS-MODEL. http://swissmodel.expasy.org/. 77. Cavalli, A.; Dezi, C.; Folkers, G.; Scapozza, L.; Recanatini, M., Three-dimensional model of the cyclin-dependent kinase 1 (CDK1): Ab initio active site parameters for molecular dynamics studies of CDKs. Proteins-Structure Function and Genetics 2001, 45 (4), 478-485. 78. Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A. E.; Berendsen, H. J., GROMACS: fast, flexible, and free. J Comput Chem 2005, 26 (16), 1701-18. 79. Pan, D. H.; Liu, J. Z.; Senese, C.; Hopfinger, A. J.; Tseng, Y., Characterization of a ligand-receptor binding event using receptor-dependent four-dimensional quantitative structure-activity relationship analysis. Journal of Medicinal Chemistry 2004, 47 (12), 3075-3088. 80. Pan, D.; Tseng, Y.; Hopfinger, A. J., Quantitative structure-based design: formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase. J Chem Inf Comput Sci 2003, 43 (5), 1591-607. 81. Tokarski, J. S.; Hopfinger, A. J., Prediction of ligand-receptor binding thermodynamics by free energy force field (FEFF) 3D-QSAR analysis: application to a set of peptidometic renin inhibitors. J Chem Inf Comput Sci 1997, 37 (4), 792-811. 82. Martins, J. P.; Barbosa, E. G.; Pasqualoto, K. F.; Ferreira, M. M., LQTA-QSAR: a new 4D-QSAR methodology. J Chem Inf Model 2009, 49 (6), 1428-36. 83. Glen, W. G.; Dunn, W. J., III; R., S. D., Principal components analysis and partial least squares regression. Tetrahedron Computer Methodology 1989, 2 (6), 349–376. 84. Rogers, D., WOLF Manual. 1994, 6.2. 85. Rogers, D.; Hopfinger, A. J., Application of Genetic Function Approximation to Quantitative Structure-Activity-Relationships and Quantitative Structure-Property Relationships. J Chem Inf Comp Sci 1994, 34 (4), 854-866. 86. Friedman, J. H., Multivariate Adaptive Reg- ression Splines. The Annals of Statistics 1991, 19 (1), 1-67. 87. DeLano, W. L.; Lam, J. W., PyMOL: A communications tool for computational models. Abstr Pap Am Chem S 2005, 230, U1371-U1372. 88. Pocket-Finder. http://www.modelling.leeds.ac.uk/pocketfinder/. 89. Rusyn, I.; Daston, G. P., Computational toxicology: realizing the promise of the toxicity testing in the 21st century. Environmental health perspectives 2010, 118 (8), 1047-50. 90. Shukla, S. J.; Huang, R.; Austin, C. P.; Xia, M., The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. Drug discovery today 2010, 15 (23-24), 997-1007. 91. Krewski, D.; Westphal, M.; Al-Zoughool, M.; Croteau, M. C.; Andersen, M. E., New directions in toxicity testing. Annual review of public health 2011, 32, 161-78. 92. Sun, H.; Xia, M.; Austin, C. P.; Huang, R., Paradigm shift in toxicity testing and modeling. The AAPS journal 2012, 14 (3), 473-80. 93. Muster, W.; Breidenbach, A.; Fischer, H.; Kirchner, S.; Muller, L.; Pahler, A., Computational toxicology in drug development. Drug discovery today 2008, 13 (7-8), 303-10. 94. Merlot, C., Computational toxicology--a tool for early safety evaluation. Drug discovery today 2010, 15 (1-2), 16-22. 95. Modi, S.; Hughes, M.; Garrow, A.; White, A., The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries. Drug discovery today 2012, 17 (3-4), 135-42. 96. Selassie, C. D.; Shusterman, A. J.; Kapur, S.; Verma, R. P.; Zhang, L. T.; Hansch, C., On the toxicity of phenols to fast growing cells. A QSAR model for a radical-based toxicity. J Chem Soc Perk T 2 1999, (12), 2729-2733. 97. Garcia-Lorenzo, A.; Tojo, E.; Tojo, J.; Teijeira, M.; Rodriguez-Berrocal, F. J.; Gonzalez, M. P.; Martinez-Zorzano, V. S., Cytotoxicity of selected imidazolium-derived ionic liquids in the human Caco-2 cell line. Sub-structural toxicological interpretation through a QSAR study. Green Chem 2008, 10 (5), 508-516. 98. Guha, R.; Schurer, S. C., Utilizing high throughput screening data for predictive toxicology models: protocols and application to MLSCN assays. Journal of computer-aided molecular design 2008, 22 (6-7), 367-84. 99. Chen, S. Z.; Jiang, M.; Zhen, Y. S., HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer chemotherapy and pharmacology 2005, 56 (2), 212-20. 100. Waldhauser, K. M.; Brecht, K.; Hebeisen, S.; Ha, H. R.; Konrad, D.; Bur, D.; Krahenbuhl, S., Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Brit J Pharmacol 2008, 155 (4), 585-595. 101. Dai, Y.; Cederbaum, A. I., Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected HepG2 cells. J Pharmacol Exp Ther 1995, 273 (3), 1497-505. 102. Cronin, M. T. D.; Schultz, T. W., Pitfalls in QSAR. J Mol Struc-Theochem 2003, 622 (1-2), 39-51. 103. Xia, M.; Huang, R.; Witt, K. L.; Southall, N.; Fostel, J.; Cho, M. H.; Jadhav, A.; Smith, C. S.; Inglese, J.; Portier, C. J.; Tice, R. R.; Austin, C. P., Compound cytotoxicity profiling using quantitative high-throughput screening. Environmental health perspectives 2008, 116 (3), 284-291. 104. Li, Q.; Wang, Y.; Bryant, S. H., A novel method for mining highly imbalanced high-throughput screening data in PubChem. Bioinformatics 2009, 25 (24), 3310-6. 105. Estabrooks, A.; Jo, T. H.; Japkowicz, N., A multiple resampling method for learning from imbalanced data sets. Comput Intell 2004, 20 (1), 18-36. 106. Ertekin, S.; Huang, J.; Bottou, L.; Giles, L., Learning on the border: active learning in imbalanced data classification. In Proceedings of the sixteenth ACM conference on Conference on information and knowledge management, ACM: Lisbon, Portugal, 2007; pp 127-136. 107. Gazzah, S.; Amara, N. E. B., New Oversampling Approaches Based on Polynomial Fitting for Imbalanced Data Sets. In Proceedings of the 2008 The Eighth IAPR International Workshop on Document Analysis Systems, IEEE Computer Society: 2008; pp 677-684. 108. Tang, Y.; Zhang, Y.-Q.; Chawla, N. V.; Krasser, S., SVMs modeling for highly imbalanced classification. Trans. Sys. Man Cyber. Part B 2009, 39 (1), 281-288. 109. Sun, A. X.; Lim, E. P.; Liu, Y., On strategies for imbalanced text classification using SVM: A comparative study. Decis Support Syst 2009, 48 (1), 191-201. 110. Xie, J. G.; Qiu, Z. D., The effect of imbalanced data sets on LDA: A theoretical and empirical analysis. Pattern Recogn 2007, 40 (2), 557-562. 111. Haykin, S. S., Neural Networks: A Comprehensive Foundation. 2nd ed.; Prentice Hall: Englewood Cliffs, NJ, 1998. 112. Breiman, L., Random Forests. Machine Learning 2001, 45 (1), 5-32. 113. Quinlan, J. R., Induction of decision trees. Mach Learn 1986, 1 (1), 81-106. 114. Judson, R.; Elloumi, F.; Setzer, R. W.; Li, Z.; Shah, I., A comparison of machine learning algorithms for chemical toxicity classification using a simulated multi-scale data model. BMC bioinformatics 2008, 9, 241. 115. Sharma, A.; Kumar, R.; Varadwaj, P. K.; Ahmad, A.; Ashraf, G. M., A comparative study of support vector machine, artificial neural network and bayesian classifier for mutagenicity prediction. Interdisciplinary sciences, computational life sciences 2011, 3 (3), 232-9. 116. Svetnik, V.; Liaw, A.; Tong, C.; Culberson, J. C.; Sheridan, R. P.; Feuston, B. P., Random forest: a classification and regression tool for compound classification and QSAR modeling. Journal of chemical information and computer sciences 2003, 43 (6), 1947-58. 117. Polishchuk, P. G.; Muratov, E. N.; Artemenko, A. G.; Kolumbin, O. G.; Muratov, N. N.; Kuz'min, V. E., Application of random forest approach to QSAR prediction of aquatic toxicity. Journal of chemical information and modeling 2009, 49 (11), 2481-8. 118. Zhao, C. Y.; Zhang, H. X.; Zhang, X. Y.; Liu, M. C.; Hu, Z. D.; Fan, B. T., Application of support vector machine (SVM) for prediction toxic activity of different data sets. Toxicology 2006, 217 (2-3), 105-19. 119. Katritzky, A. R.; Kuanar, M.; Slavov, S.; Hall, C. D.; Karelson, M.; Kahn, I.; Dobchev, D. A., Quantitative correlation of physical and chemical properties with chemical structure: utility for prediction. Chemical reviews 2010, 110 (10), 5714-89. 120. von Korff, M.; Sander, T., Toxicity-indicating structural patterns. Journal of chemical information and modeling 2006, 46 (2), 536-44. 121. Kazius, J.; McGuire, R.; Bursi, R., Derivation and validation of toxicophores for mutagenicity prediction. Journal of medicinal chemistry 2005, 48 (1), 312-20. 122. Xue, Y.; Li, Z. R.; Yap, C. W.; Sun, L. Z.; Chen, X.; Chen, Y. Z., Effect of molecular descriptor feature selection in support vector machine classification of pharmacokinetic and toxicological properties of chemical agents. Journal of chemical information and computer sciences 2004, 44 (5), 1630-8. 123. Tseng, Y. J.; Hopfinger, A. J.; Esposito, E. X., The great descriptor melting pot: mixing descriptors for the common good of QSAR models. Journal of computer-aided molecular design 2012, 26 (1), 39-43. 124. Renner, S.; Fechner, U.; Schneider, G., Pharmacophores and Pharmacophore Searches. Wiley-VCH, Weinheim, Germany, 2006; Vol. 32, p 49-79. 125. Su, B. H.; Tu, Y. S.; Esposito, E. X.; Tseng, Y. J., Predictive toxicology modeling: protocols for exploring hERG classification and Tetrahymena pyriformis end point predictions. Journal of chemical information and modeling 2012, 52 (6), 1660-73. 126. Shen, M. Y.; Su, B. H.; Esposito, E. X.; Hopfinger, A. J.; Tseng, Y. J., A Comprehensive Support Vector Machine Binary hERG Classification Model Based on Extensive but Biased End Point hERG Data Sets. Chem Res Toxicol 2011, 24 (6), 934-949. 127. Senese, C. L.; Duca, J.; Pan, D.; Hopfinger, A. J.; Tseng, Y. J., 4D-Fingerprints, Universal QSAR and QSPR Descriptors. J. Chem. Inf. Comput. Sci. 2004, 44 (5), 1526-1539. 128. Molecular Operating Environment (MOE), Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7: 2011. 129. MOE (Molecular Operating Environment), 2008.10; Chemical Computing Group, Inc.: Montreal, Canada, 2008. 130. Lin, A. QuaSAR-Descriptor. November 2012; Available from: http://www.chemcomp.com/journal/descr.htm. 131. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G., 'Scaffold-Hopping' by Topological Pharmacophore Search: A Contribution to Virtual Screening. Angew Chem Int Ed Engl 1999, 38 (19), 2894-2896. 132. Vapnik, V. N., Statistical Learning Theory. Wiley: New York, 1998. 133. Vapnik, V. N., The Nature of Statistical Learning Theory. Springer, 2000. 134. Liaw, A.; Wiener, M., Classification and Regression by randomForest. R News 2002, pp 18-22. 135. Team, R. D. C. R: A language and environment for statistical computing., R Foundation for Statistical Computing. Vienna, Austria, 2011. 136. Chang, C.-C.; Lin, C.-J., LIBSVM: A library for support vector machines. ACM Trans. Intell. Syst. Technol. 2011, 2 (3), 1-27. 137. Cohen, J., A Coefficient of Agreement for Nominal Scales. Educ Psychol Meas 1960, 20 (1), 37-46. 138. Rucker, C.; Rucker, G.; Meringer, M., y-Randomization and its variants in QSPR/QSAR. J Chem Inf Model 2007, 47 (6), 2345-2357. 139. SCHWARTZMAN, R. A.; CIDLOWSKI, J. A., Apoptosis: The Biochemistry and Molecular Biology of Programmed Cell Death. Endocrine Reviews 1993, 14 (2), 133-151. 140. Groot, R. D.; Rabone, K. L., Mesoscopic Simulation of Cell Membrane Damage, Morphology Change and Rupture by Nonionic Surfactants. Biophysical Journal 2001, 81 (2), 725-736. 141. Nakamura, E.; Tokuyama, H.; Yamago, S.; Shiraki, T.; Sugiura, Y., Biological Activity of Water-Soluble Fullerenes. Structural Dependence of DNA Cleavage, Cytotoxicity, and Enzyme Inhibitory Activities Including HIV-Protease Inhibition. Bulletin of the Chemical Society of Japan 1996, 69 (8), 2143-2151. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61363 | - |
dc.description.abstract | 本論文中提出三項研究主題,第一章說明,N-甲基-D-天冬氨酸(NMDA)受體已被發現參與精神分裂症相關的神經病理,並已知D-氨基酸氧化酶(DAAO)在NMDA受體的激活過程中發揮重要的作用,因此DAAO被推斷與精神分裂的致病機轉有關。在本研究中,我們利用老藥新用的方式,針對已知的藥物進行DAAO可能的抑制劑篩選,透過以結構為基礎(structure-based)的虛擬篩選(virtual screening)最後進行了八個候選化合物的DAAO酵素實驗,其中有四個化合物對DAAO的抑制能力其IC50在1~10 μM之間,又以5-O-去甲基-奧美拉唑(5-O-desmethyl-omeprazole)有最佳的抑制力,其為一種用於治療消化不良、潰瘍和胃食道逆流藥物的代謝物,他的IC50值為1.19 μM。
第二章中,我們針對化合物的選擇性和藥物的修改方向透過基於配體(ligand-based)的定量構效關係(QSAR)模型組合,發展一個偏優化(biased optimization)的方法。多目標藥物具有治療多種疾病的潛力,但可能也具有不良的副作用,因此,將化合物的作用導向我們想要的方向變的十分重要,我們選擇了兩系列作用於HER2/EGFR和CDKs/CK1的化合物,說明QSAR不只可以針對藥物的專一性進行優化,也可應用於藥物的選擇性,QSAR回歸模型的係數指出分子上哪些位置和特性對於分子的選擇性有決定性的影響。我們還針對分子結合到相關受體上的情況進行分析,說明基於配體的方法仍可以反映出和受體結合後的差異,並可避免相關結晶結構未知的問題。 在第三章使用支持向量機(SVM)、各種分子特徵及不同取樣方法的組合對於多個化合物針對Jurkat這個細胞株進行細胞毒性的分類與預測,該細胞毒性為不平衡的數據組成,也就是少數的化合物具有細胞毒性,多數則無,這將不利預測模型的建構。我們透過SVM和各種分子特徵,包括:4D-FPs、 MOE (1D, 2D and 2½D)、noNP+MOE和CATS2D等方法,和前人使用隨機森林(random forest)法的CATS2D分子特徵所建構出來的模型之預測利進行比較,使用SVM搭配超取樣(oversample)的方式,不論是對於數據的訓練或是額外的預測都有較佳的結果。 | zh_TW |
dc.description.abstract | Three works are proposed in this dissertation. In the first chapter, the N-methyl-D-aspartic acid (NMDA) receptor has previously been reported to be involved in the neuropathology of schizophrenia. D-amino acid oxidase (DAAO) has been found to play an important role in the activation process of the NMDA receptor and consequently has also been hypothesized to be involved in the pathogenesis of schizophrenia. To determine if existing drugs and compounds could be utilized as potential DAAO inhibitors through drug repurposing, a structure-based virtual screening was performed utilizing the DrugBank database. Eight commercially available compounds were identified and selected for further analysis with a DAAO enzymatic assay, with four of these compounds confirmed to have DAAO inhibitory activity with IC50 values ranging from 1 to 10 μM. 5-O-desmethyl-omeprazole, a metabolite of omeprazole, an agent widely used to treat dyspepsia, peptic ulcer disease and gastroesophageal reflux disease, was identified in this study as the most potent inhibitor of DAAO with an IC50 value of 1.19 μM.
In Chapter 2, the purpose of this study was to develop a biased optimization method that responds to the selectivities of compounds and to modify the drug optimization process through simple ligand-based quantitative structure–activity relationship (QSAR) model combinations. Multi-target drugs not only have the potential to treat multiple diseases but also possess a higher probability of undesirable side effects. Therefore, we sought to develop inhibitors that possess only the activities we deemed important. We chose two series of compounds to act on HER2/EGFR and CDKs/CK1 and demonstrated that the QSAR methodology for drug specificity can be extended to drug selectivity. The coefficients in the regression models indicate which molecular positions and replacements are important for determining selectivity. We also analyzed ligand-binding conditions to demonstrate that the ligand-based method describes differences in the receptor structures and avoids estimation problems that arise when the crystal structures of the complexes are unknown. In Chapter 3, the research presented in this study focuses on the use of support vector machines, a machine learning method, various classes of molecular descriptors and different sampling techniques to overcome overfitting to classify compounds for cytotoxicity with respect to the Jurkat cell line. The cell cytotoxicity data set is imbalanced (few active compounds and very many inactive compounds) and the ability of the predictive modeling methods is adversely affected in these situations. The SVM models were constructed from 4D-FPs, MOE (1D, 2D and 2½D), noNP+MOE and CATS2D trial descriptors pools and compared to the predictive abilities of CATS2D-based random forest models. Compared to previous studies, the SVM models built from oversampled data sets exhibited better predictive abilities for the training and external test sets. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T13:01:39Z (GMT). No. of bitstreams: 1 ntu-102-D95423003-1.pdf: 4393675 bytes, checksum: 686b0238b28b0687b556b9a5267d16c8 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 口試委員審訂書…………………………………………………i
ACKNOWLEDGEMENTS…………………………………....ii 中文摘要……………………………………………………….iii ABSTRACT……………………………………………………..v LIST OF ABBREVIATIONS…………………………………xii LIST OF FIGURES………………………………………......xiii LIST OF TABLES……………………………………………..xv CHAPTER I. Identification of New D-amino Acid Oxidase Inhibitors Through Drug Repurposing 1 1.1 Introduction 1 1.1.1 Background 1 1.1.2 Drug Repurposing 3 1.2 Materials and Methods 5 1.2.1 2D Similarity 5 1.2.2 Virtual Screening 5 1.2.3 Molecular Dynamic Simulation (MDS) 6 1.2.4 Materials 7 1.2.5 DAAO enzymatic assay 7 1.2.6 Purity Determination 9 1.3 Results and Discussion 20 1.3.1 Virtual Screening 20 1.3.2 Selection of Candidate Compounds 20 1.3.3 Experimental Evaluation 23 1.3.4 5-O-Desmethyl-omeprazole Identified as the Most Potent DAAO Inhibitor through Drug Repurposing and Comparison with Current Known DAAO Inhibitors 25 1.3.5 Other Potent DAAO Inhibitor 28 1.4 Conclusion 29 II. RIBOSE: A Receptor-Independent Biased Optimization Protocol for Selectivity 30 2.1 Introduction 30 2.2 Materials and Methods 36 2.2.1 Data Sets 36 2.2.2 Methods 42 2.2.2.1 Molecular Dynamic Simulation (MDS) 44 2.2.2.2 Grid Analysis 44 2.2.2.3 Variable Selection and Model Validation 45 2.3 Results and Discussion 47 2.3.1 The Initial Selectivity Analysis from Receptor-Based Studies 47 2.3.1.1 HER2/EGFR Set 47 2.3.1.2 CDK1/CDK5/CK1 Set 50 2.3.2 RIBOSE Model Generation and Prediction Power Validation 53 2.3.2.1 Increase HER2 Activities and Decrease EGFR Activities in the Pyrrolo[3,2-d]pyrimidine Series 54 2.3.2.2 Increase the CDK5 Activities and Decrease the CDK1 Activities in the Roscovitine-derived Series 60 2.3.2.3 Increase the CDK5 and CK1 Activities and Decrease the CDK1 Activities Using a Roscovitine-derived Series 66 2.3.2.4 Increase the CDK1 and Decrease the CK1 Activities Using a Roscovitine-derived Series (the Reverse Changes of the Selectivity) 72 2.3.3 The Interaction Pattern Analysis for the Binding Compounds from Low to High Selectivity by RIBOSE Model 75 2.4 Conclusion 78 III. Application of Computational Models for Cytotoxicity Data Analysis 80 3.1 Introduction 80 3.1.1 Background 80 3.1.2 Different Trial Descriptor Pools, Data Set Composition, Oversampling Strategies and Model Construction Methods for the Cytotoxicity Prediction 83 3.2 Materials and Methods 86 3.2.1 Materials 86 3.2.1.1 Experiment measurement of Cell Viability data 86 3.2.1.2 Data Sets 86 3.2.2 Methods 89 3.2.2.1 Molecular Descriptors 89 3.2.2.2 Rebalancing the Data Set 93 3.2.2.3 Model Creation Methods 94 3.2.2.4 Model Evaluation 96 3.2.2.5 Molecular similarity 98 3.3 Results and Discussion 100 3.3.1 Prediction Models of Cell Viability 101 3.3.2 SVM Model Constructed from the Complete AID 426 Data Set 102 3.3.3 SVM Model Constructed from the Jurkat Cell Specific Data 104 3.3.4 Oversampling the Imbalanced Data Sets 106 3.3.5 Descriptors, Sampling, Modeling and Filtering Contribution in Classification Model 111 3.3.6 Similarity of Training Data Set and Testing Data Set 117 3.3.7 Significant Molecular Features of the Optimal Cytotoxic Predictive Model 123 3.4 Conclusion 128 BIBLIOGRAPHY 130 | |
dc.language.iso | en | |
dc.title | 老藥新用及細胞毒性分析與選擇性偏優化 | zh_TW |
dc.title | Cytotoxicity Data Analysis and Biased Optimization for Selectivity in Drug Development and Drug Repurposing | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 劉玉麗,鄧哲明,顧記華 | |
dc.subject.keyword | D-氨基酸氧化酶,虛擬篩選,老藥新用,偏優化,四維定量構效關係,選擇性,不平衡數據組成,細胞毒性模型,分類預測模型, | zh_TW |
dc.subject.keyword | DAAO,Virtual screening,Drug repurposing,Biased optimization,4D-QSAR, Selectivity,Imbalanced data,Cytotoxicity modeling,Classification predictive model, | en |
dc.relation.page | 143 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-08-07 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 4.29 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。